TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06822426: Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults And Adolescent Participants Receiving Total Parenteral Nutrition

Sponsor: CorMedix Therapeutics · Phase: PHASE3 · Area: INFECTIOUS_VACCINE · Target Enrollment: 200 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,214,596

Rescue Site Savings

+$2,129,148

Unlock Full NCT06822426 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06822426 Rescue Dossier →